Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 SBRT with or without pembrolizumab for unresectable stage I-II NSCLC
NL-OMON59917Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing SBRT + pembrolizumab with SBRT + placebo (2 arms). Primary endpoint: Event-Free Survival. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59917.